Full Press Release Details
Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
David Poppers to present on his initial experience with Lucid's EsoCheck and EsoGuard
YORK, May 13, 2021 (GLOBE NEWSWIRE) - PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a
highly differentiated, multi-product, commercial-stage medical technology company, and its major subsidiary Lucid Diagnostics Inc. ("Lucid"),
announced today that David Poppers, M.D. Ph.D. will be presenting data on his team's initial experience using Lucid's EsoCheck
Esophageal Cell Collection Device and EsoGuard Esophageal DNA Test at the upcoming Digestive Disease Week 2021
medical conference, which will be held virtually May 21-23, 2021.
Poppers is Clinical Professor, Division of Gastroenterology and Hepatology at NYU Langone Medical Center in New York City, and an expert
in advanced endoscopy and esophageal disease. His presentation, entitled EsoCheck/EsoGuard: a Novel, Simple, Outpatient Technology
for the Early Detection of Esophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma, will be presented during poster session
7110 to be held on Sunday, May 23, 2021 between 12:15 PM and 1 PM EDT.
Disease Week (DDW) is the largest international gathering of physicians, researchers, and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal surgery. DDW is jointly sponsored by the American Association for the Study
of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy
(ASGE) and the Society for Surgery of the Alimentary Tract (SSAT).
Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing
unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its
major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer
and cancer - the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. Its
GI Health division also includes the complementary EsoCure Esophageal Ablation Device with Caldus Technology. Its Minimally
Invasive Interventions markets its CarpX Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include
Infusion Therapy (PortIO Implantable Intraosseus Vascular Access Device and NextFlo Intravenous Infusion Set), and Emerging
Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information,
on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with
press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that
are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed's management,
are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties
that may cause such differences include, among other things, our ability to complete our strategic initiatives, volatility in the price
of PAVmed's common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent
in research and development, including the cost and time required advance PAVmed's products to regulatory submission; whether regulatory
authorities will be satisfied with the design of and results from PAVmed's preclinical studies; whether and when PAVmed's
products are cleared by regulatory authorities; the effectiveness of our marketing initiatives; the establishment of government and private
payment insurance coverage; market acceptance of PAVmed's products once cleared and commercialized; our ability to raise additional
funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many
of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance
of the COVID-19 pandemic, including the extent of its effect on the Company's financial and operational results, to be dictated
by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties
may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and
many of them are beyond PAVmed's control. For a further list and description of these and other important risks and uncertainties
that may affect PAVmed's future operations, see Part I, Item IA, "Risk Factors," in PAVmed's most recent Annual
Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors"
in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation
to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances
on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the
forward-looking statements.
of Investor Relations
Heins / Katie Gallagher
491-7042 / (617) 792-3937